Back

Temporal trends in the use of P2Y12 inhibitors over 15 years and their impact on in-hospital bleeding and mortality among patients with acute myocardial infarction in Switzerland

28 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Personalising antithrombotic therapy in percutaneous coronary intervention for acute coronary syndromes: balancing ischaemic protection and bleeding risk Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Jan Loosli

UZH - Epidemiology, Biostatistics and Prevention Institute, Zurich (Switzerland)

5 More presentations in this session

Presentation thumbnail
Impact of intravascular imaging guidance on the effects of aspirin-free strategy for percutaneous coronary intervention for acute coronary syndrome: a post-hoc analysis from the STOPDAPT-3 trial
Doctor K. Takabayashi (Shiga, JP)
Abstract Slides
Presentation thumbnail
Impact of routine cardiovascular medications on contrast induced nephropathy post percutaneous coronary intervention: a national experience
Doctor O. Alameen (Doha, QA)
Abstract Slides
Presentation thumbnail
Timing of P2Y12 inhibitor administration in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis
Doctor T. Theodoropoulou (Athens, GR)
Abstract Slides
Presentation thumbnail
Standard versus extended dual antiplatelet therapy after pci in acute coronary syndrome: a systematic review and meta-analysis
Mr A. Gasca (Cali, CO)
Abstract Slides
Presentation thumbnail
Early aspirin withdrawal to P2Y12 monotherapy after PCI for ACS: a systematic review and meta-analysis of randomized controlled trials
Professor M. Saffi (Porto Alegre, BR)
Abstract Slides

Access the full session

Session thumbnail
Personalising antithrombotic therapy in percutaneous coronary intervention for acute coronary syndromes: balancing ischaemic protection and bleeding risk

The Event

Event poster

ESC Congress 2026

28 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of clopidogrel, ticagrelor, and prasugrel in an all-comers population of patients with ST-segment elevation myocardial infarction
31 August 2020
thumbnail
Congress Presentation
Temporal trends in the use of levosimendan in a tertiary hospital: a retrospective study
29 June 2021
thumbnail
Congress Presentation
Trends in P2Y12 inhibitor use after acute coronary syndromes: insights from the ProACS registry
1 September 2025
thumbnail
Congress Presentation
Cross-sectional analysis of primary PCI provision and AMI mortality across europe: accounting for economic and disease burden
20 February 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources